Last reviewed · How we verify

NCT04708184

A Study to Assess Relative Bioavailability of and Effect of Food on a New Oral Tablet Formulation of GLPG3970

Completed Phase 1 Last updated 25 March 2021
What this trial tests

Phase 1 trial testing GLPG3970 oral solution in Healthy in 12 participants. Completed in 25 February 2021.

Timeline
11 January 2021
Primary endpoint
25 February 2021
25 February 2021

Quick facts

Lead sponsorGalapagos NV
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposetreatment
Enrollment12
Start date11 January 2021
Primary completion25 February 2021
Estimated completion25 February 2021
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Galapagos NV — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a study to assess the relative bioavailability of a GLPG3970 oral tablet formulation compared to an oral solution formulation and the effect of food on the bioavailability of a single dose of the oral tablet formulation of GLPG3970. It will also evaluate the safety and tolerability of a single dose of GLPG3970.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of GLPG3970 oral solution

Trials testing the same drug.

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Galapagos NV trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04708184.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing